Clinical Evidence

Comprehensive guide to the EU's new Breakthrough Device (BtX) framework under MDCG 2025-9 and the EMA pilot program launching Q2 2026. Covers eligibility criteria, application process, benefits for manufacturers, comparison with the FDA Breakthrough Device Program, and what this means for IVD companies.

The FDA's April 2026 real-time clinical trials initiative uses AI and cloud computing to monitor trial data as it is generated. This guide explains how the program works, the Paradigm Health platform, implications for medical device clinical investigations, and what sponsors must prepare to participate.

Practical guide to building the critical-task matrix for auto-injector and pen-injector human factors validation — task identification from URRA, needle shield removal, site selection, dose confirmation, hold time, misfire recovery, training decay, disposal, use-error root cause analysis, and FDA/IEC 62366 evidence expectations.

How to prepare the consultation file for IVDR companion diagnostics — notified body submission to EMA or national medicinal product authorities, package contents, analytical and clinical performance evidence, drug label alignment, timing, deficiency risks, and the Team-NB V2 decision flowchart for significant changes.

How to design a PMCF survey under EU MDR that Notified Bodies accept as Level 4 clinical evidence — sample frame construction, inclusion/exclusion criteria, endpoint mapping to CER claims, acceptance criteria, statistical power, bias controls, adverse event capture, and when surveys alone are insufficient.

Practical playbook for responding to Notified Body deficiencies on SSCP documents under EU MDR — response table format, clinical benefit wording fixes, residual risk language, patient readability, CER/IFU alignment, translation consistency, and EUDAMED publication readiness.

How Good Clinical Practice applies to medical device clinical trials — navigating ISO 14155:2026 and ICH E6(R3), sponsor and investigator responsibilities, informed consent, safety reporting, and audit readiness.

Dedicated CLIA waiver playbook for IVD manufacturers — covering waived, moderate, and high complexity categories, CW submission content, flex studies, lay-user studies, the Dual 510(k) + CLIA Waiver pathway, review timelines, common deficiencies, and real-world examples.

Section-by-section CER template for EU MDR compliance — covering clinical evaluation plan, device description, literature search protocol, data appraisal tables, equivalence justification, benefit-risk analysis, PMCF linkage, evidence traceability matrix, and Notified Body-ready formatting. Free alternative to gated competitor templates.

Practical guide to using digital twins, synthetic data, and computational modeling in medical device regulatory submissions — covering FDA CM&S credibility guidance, ASME V&V 40, in silico clinical trials, synthetic control arms, model validation pitfalls, and documentation strategies.

Practical regulatory guide for home-use and self-test in vitro diagnostic devices — covering FDA pathways (OTC, prescription home use, CLIA waiver), EU IVDR self-testing requirements, human factors and lay-user usability, specimen collection errors, labeling requirements, DTC vs provider-ordered models, and post-market surveillance for consumer diagnostics.

Comprehensive regulatory and validation strategy for next-generation sequencing (NGS) in vitro diagnostic devices — covering FDA pathways (510(k), De Novo, PMA), proposed CDx reclassification, EU IVDR classification, wet lab and bioinformatics pipeline validation, variant calling, reference databases, clinical validity, cybersecurity, and post-market obligations.

Practical PMCF Plan template aligned with MDCG 2020-7 and EU MDR Annex XIV Part B — covering objectives derivation from CER gaps, method selection (registries, surveys, studies, literature), endpoint definition, sample size logic, schedule, triggers, PMCF evaluation report structure, and PMS integration.

Regulatory strategy guide for surgical robot manufacturers — covering FDA classification (510(k), De Novo, PMA), autonomy levels, software controls (IEC 62304), electrical safety (IEC 60601), usability (IEC 62366), clinical evidence expectations, EU MDR requirements, training programs, and post-market surveillance.

On March 20, 2026, the European Commission adopted two delegated regulations expanding the Well-Established Technology (WET) list under EU MDR. C(2026) 1798 exempts additional implantable and Class III devices from clinical investigations. C(2026) 1809 simplifies conformity assessment for Class IIb implantable devices. This guide covers what changed, which devices qualify, WET criteria, and practical steps for manufacturers.

Complete guide to benefit-risk analysis for medical devices — ISO 14971:2019 residual risk evaluation, EU MDR AFAP requirements, FDA benefit-risk factors for PMA/De Novo/510(k), MDCG guidance, practical examples, and documentation best practices.

Complete guide to demonstrating clinical equivalence under EU MDR Article 61 and Annex XIV — technical, biological, and clinical characteristics per MDCG 2020-5, differences from MEDDEV 2.7/1 Rev. 4, data access requirements, gap analysis, and practical examples for CE marking.

How to design and run decentralized clinical trials for medical devices — FDA final guidance, hybrid vs fully remote models, digital endpoints, wearable data capture, eConsent, and step-by-step implementation framework.

Complete guide to validating Electronic Data Capture (EDC) systems for medical device clinical trials — 21 CFR Part 11 compliance, EU GMP Annex 11, ICH E6(R2)/(R3) GCP requirements, GAMP 5 risk-based validation approach, IQ/OQ/PQ methodology, audit trail requirements, ALCOA+ principles, vendor vs sponsor responsibilities, study-specific validation, and common FDA inspection findings.

Step-by-step guide to creating a compliant literature search protocol for medical device clinical evaluation under EU MDR Article 61 and Annex XIV — MEDDEV 2.7/1 Rev. 4 methodology, PICO framework, database selection, inclusion/exclusion criteria, critical appraisal, PRISMA documentation, and Notified Body expectations.